Method for improving killing activity of NK cells
By using the combination of interleukin-10, interleukin-13 and interleukin-18 in NK cell culture, combining specific amino acids and other nutrients, and optimizing the culture conditions, the insufficient killing activity of NK cells was solved. Problem, efficient NK cell expansion and high killing activity are achieved, suitable for tumor treatment.
Patent Information
- Application Number
- CN202411379907.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-09-30
AI Technical Summary
The prior art is difficult to effectively improve the killing activity of NK cells, and the content of NK cells in peripheral blood is insufficient to meet clinical needs, which affects its application in the treatment of diseases such as autoimmune diseases and tumors.
Using a culture medium containing interleukin-10, interleukin-13 and interleukin-18, combining a specific proportion of amino acids, glutathione and silk peptide powder, optimized culture conditions such as temperature, CO2 concentration and The fluid replenishment regimen significantly improves the killing activity and amplification efficiency of NK cells.
It significantly improves the killing activity and amplification efficiency of NK cells, and obtains high-purity and high-killing activity NK cells. It is suitable for the preparation of anti-tumor drugs, especially for non-small cell lung cancer, chronic myeloid leukemia, colorectal cancer and breast cancer. The tumor has significant effects.
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of NK cell culture, and in particular to a method for improving the killing activity of NK cells. Background Art
[0002] Natural killer cells (NK cells) are a type of lymphocytes that are parallel to T cells and B cells. They are the main elements of the natural immune system. In addition to participating in the innate immune response, NK cells also play an important regulatory role in adaptive immune regulation. Related studies have found that NK cells can play a major role in a variety of pathological processes such as pathogenic microbial infection, autoimmune diseases and tumors.
[0003] NK cells directly recognize target cells mainly through binding to MHC class I molecules through their surface receptors, and do not require the participation of antigen presenting cells. When NK cells are activated, they can kill target cells through cytotoxicity, and on the other hand, they can secrete cytokines such as interleukin 2 and interferon-γ to activate other effector lymphocytes.
[0004] The content of NK cells in peripheral blood lymphocytes is only about 10%, and the content of NK cells in peripheral blood is far from meeting clinical needs. Currently, NK cells are mainly expanded by cytokine stimulation, but there is still a certain gap between the NK cells expanded by the above method and clinical needs. Moreover, for the further use of NK cells, the killing activity of NK cells still needs to be improved. Therefore, finding a method to improve the killing activity of NK cells will help to better play the role of NK cells and apply them in the treatment of autoimmune diseases, tumors and other diseases. Summary of the invention
[0005] The object of the present invention is to provide a method for improving the killing activity of NK cells.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a method for improving the killing activity of NK cells, comprising the following steps:
[0008] (1) Separating peripheral blood to obtain PBMC cells;
[0009] (2) separating the PBMC cells to obtain NK cells;
[0010] (3) inoculating NK cells into NK cell culture medium for cultivation;
[0011] The NK cell culture medium comprises: 1-2 g / L L-lysine, 0.2-0.6 g / L methionine, 1-2 g / L L-tryptophan, 1-2 g / L L-proline, 6-10 g / L glutathione, 5-9 g / L coenzyme 1, 1-2 g / L silk peptide powder, 60-70 mL / L human plasma, 8-12 g / L human serum albumin, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13, 0.3-0.5 μL / mL interleukin-18, and the rest is a basic culture medium.
[0012] Preferably, the basal culture medium is Lonza X-VIVO 15 serum-free culture medium, SCGM serum-free culture medium or Takara NK cell serum-free culture medium.
[0013] Preferably, the culture temperature is 37-38°C and the volume concentration of CO2 is 5%-6%.
[0014] Preferably, the culture time is 13 to 15 days.
[0015] Preferably, the inoculated cell density is 7 to 9×10 5 Pieces / mL.
[0016] Preferably, during the culture process, the early replenishment medium is added every 2 to 3 days from the 0th to the 7th day of culture, and the late replenishment medium is added every 2 to 3 days thereafter; after replenishment, the cell density is always maintained at 7 to 9×10 5 Pieces / mL.
[0017] Preferably, the initial replenishment medium comprises: 60-70 mL / L human plasma, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13 and 0.3-0.5 μL / mL interleukin-18, and the rest is basal medium.
[0018] Preferably, the late-stage rehydration culture medium comprises: 0.2-0.3 μL / mL interleukin-10, 0.5-0.6 μL / mL interleukin-13 and 0.6-0.7 μL / mL interleukin-18, and the rest is basal culture medium.
[0019] The present invention also provides the use of NK cells prepared by the method for improving the killing activity of NK cells in the preparation of anti-tumor drugs.
[0020] Preferably, the tumor is non-small cell lung cancer, chronic myeloid leukemia, colorectal cancer or breast cancer.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] NK cells with significantly improved killing activity can be obtained by culturing NK cells in a culture medium containing interleukins. The present invention uses three interleukins: interleukin-10, interleukin-13, and interleukin-18 in combination, and the killing activity of NK cells is significantly improved. If other types of interleukins are used instead, the effect is far inferior to the present invention.
[0023] The amino acids used in the present invention are all non-polar amino acids, which can effectively shorten the hysteresis period of NK cell growth, so that they can be expanded and passaged as soon as possible. The silk peptide powder added to the culture medium has a protective effect and can alleviate the influence of external stimulation on the growth of mycoplasma. Glutathione can protect cells from oxidative stress, and helps to form a favorable redox environment inside and outside the cells, and also helps to shorten the hysteresis period of NK cell growth.
[0024] The culture medium provided by the present invention also adds NK cell growth activators, including coenzyme 1. The addition of the above components activates the growth of NK cells and promotes the expansion of NK cells. This is because coenzyme 1 promotes the smooth progress of certain key metabolic pathways, provides the necessary energy and intermediates for cell growth and division, thereby facilitating the increase in cell number and playing a growth activation role.
[0025] The method of the present invention can rapidly and massively proliferate NK cells while ensuring a high activity rate of NK cells, thereby obtaining NK cells with high purity and high cytotoxic activity. DETAILED DESCRIPTION
[0026] The present invention provides a method for improving the killing activity of NK cells, comprising the following steps:
[0027] (1) Separating peripheral blood to obtain PBMC cells;
[0028] (2) separating the PBMC cells to obtain NK cells;
[0029] (3) inoculating NK cells into NK cell culture medium for cultivation;
[0030] The NK cell culture medium comprises: 1-2 g / L L-lysine, 0.2-0.6 g / L methionine, 1-2 g / L L-tryptophan, 1-2 g / L L-proline, 6-10 g / L glutathione, 5-9 g / L coenzyme 1, 1-2 g / L silk peptide powder, 60-70 mL / L human plasma, 8-12 g / L human serum albumin, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13, 0.3-0.5 μL / mL interleukin-18, and the rest is a basic culture medium;
[0031] Preferably, 1.5 g / L L-lysine, 0.3-0.5 g / L methionine, 1.5 g / L L-tryptophan, 1.5 g / L L-proline, 7-9 g / L glutathione, 6-8 g / L coenzyme 1, 1.5 g / L silk peptide powder, 62-68 mL / L human plasma, 9-11 g / L human serum albumin, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13, 0.4 μL / mL interleukin-18, and the rest are basal culture medium; One step preferably comprises 1.5 g / L L-lysine, 0.4 g / L methionine, 1.5 g / L L-tryptophan, 1.5 g / L L-proline, 8 g / L glutathione, 7 g / L coenzyme 1, 1.5 g / L silk peptide powder, 64-66 mL / L human plasma, 10 g / L human serum albumin, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13, 0.4 μL / mL interleukin-18, and the rest is the basal medium; more preferably 1.5 g / L L-lysine, 0.4g / L methionine, 1.5g / L L-tryptophan, 1.5g / L L-proline, 8g / L glutathione, 7g / L coenzyme 1, 1.5g / L silk peptide powder, 65mL / L human plasma, 10g / L human serum albumin, 0.17μL / mL interleukin-10, 0.3μL / mL interleukin-13, 0.4μL / mL interleukin-18, and the rest is basal culture medium.
[0032] In the present invention, the basal culture medium is Lonza X-VIVO 15 serum-free culture medium, SCGM serum-free culture medium or Takara NK cell serum-free culture medium; preferably Lonza X-VIVO 15 serum-free culture medium.
[0033] In the present invention, the culture temperature is 37-38°C, and the volume concentration of CO2 is 5%-6%; preferably, the culture temperature is 37°C, and the volume concentration of CO2 is 5%.
[0034] In the present invention, the culture time is 13 to 15 days, preferably 14 days.
[0035] In the present invention, the inoculated cell density is 7 to 9×10 5 / mL; preferably 8×10 5 Pieces / mL.
[0036] In the present invention, during the culture process, the early replenishment medium is supplemented every 2 to 3 days from the 0th to the 7th day of culture, and the late replenishment medium is supplemented every 2 to 3 days thereafter; preferably, the early replenishment medium is supplemented every 3 days from the 0th to the 7th day of culture, and the late replenishment medium is supplemented every 3 days thereafter.
[0037] In the present invention, during the culture process, the cell density is always maintained at 7 to 9×10 5 / mL; preferably 8×10 5 Pieces / mL.
[0038] In the present invention, the early replenishment culture medium comprises: 60-70 mL / L human plasma, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13 and 0.3-0.5 μL / mL interleukin-18, and the rest is a basal culture medium; preferably 62-68 mL / L human plasma, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13 and 0.4 μL / mL interleukin-18, and the rest is a basal culture medium; further preferably 65 mL / L human plasma, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13 and 0.4 μL / mL interleukin-18, and the rest is a basal culture medium.
[0039] In the present invention, the late rehydration medium comprises: 0.2-0.3 μL / mL interleukin-10, 0.5-0.6 μL / mL interleukin-13 and 0.6-0.7 μL / mL interleukin-18, and the rest is basal medium; preferably 0.25 μL / mL interleukin-10, 0.55 μL / mL interleukin-13 and 0.65 μL / mL interleukin-18, and the rest is basal medium.
[0040] The present invention also provides the use of NK cells prepared by the method for improving the killing activity of NK cells in the preparation of anti-tumor drugs.
[0041] In the present invention, the tumor is non-small cell lung cancer, chronic myeloid leukemia, colorectal cancer or breast cancer; preferably chronic myeloid leukemia.
[0042] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0043] Example 1
[0044] A method for improving the killing activity of NK cells, comprising the following steps:
[0045] (1) collecting peripheral blood, separating and collecting human peripheral blood mononuclear cells using a lymphocyte separation solution, and washing to obtain human peripheral blood mononuclear cells;
[0046] (2) Isolating NK cells from PBMC cells using an NK cell isolation kit;
[0047] (3) The obtained NK cells were inoculated into NK cell culture medium and cultured for 13 days; the culture temperature was 38°C, the volume concentration of CO2 was 6%; the inoculated cell density was 9×10 5 Pieces / mL.
[0048] (4) During the 0th to 7th day of culture, the early rehydration medium was added every 2 days, and the late rehydration medium was added every 2 days thereafter; the cell density was always maintained at 9×10 5 Pieces / mL.
[0049] The initial rehydration medium is: 60 mL / L human plasma, 0.16 μL / mL interleukin-10, 0.2 μL / mL interleukin-13 and 0.3 μL / mL interleukin-18, and the rest is Takara NK cell serum-free medium.
[0050] The late rehydration medium is: 0.2 μL / mL interleukin-10, 0.5 μL / mL interleukin-13 and 0.6 μL / mL interleukin-18, and the rest is Takara NK cell serum-free medium.
[0051] The NK cell culture medium is: 1g / L L-lysine, 0.2g / L methionine, 1g / L L-tryptophan, 1g / L L-proline, 6g / L glutathione, 5g / L coenzyme 1, 1g / L silk peptide powder, 60mL / L human plasma, 8g / L human serum albumin, 0.16μL / mL interleukin-10, 0.2μL / mL interleukin-13, 0.3μL / mL interleukin-18, and the rest is TakaraNK cell serum-free culture medium.
[0052] Example 2
[0053] A method for improving the killing activity of NK cells, comprising the following steps:
[0054] (1) collecting peripheral blood, separating and collecting human peripheral blood mononuclear cells using a lymphocyte separation solution, and washing to obtain human peripheral blood mononuclear cells;
[0055] (2) Isolating NK cells from PBMC cells using an NK cell isolation kit;
[0056] (3) The obtained NK cells were inoculated in NK cell culture medium and cultured for 15 days; the culture temperature was 37.5°C, the volume concentration of CO2 was 5.5%; the inoculated cell density was 7×10 5 Pieces / mL.
[0057] (4) During the 0th to 7th day of culture, the early rehydration medium was added every 3 days, and the late rehydration medium was added every 3 days thereafter; the cell density was always maintained at 7×10 5 Pieces / mL.
[0058] The initial rehydration medium is: 70 mL / L human plasma, 0.18 μL / mL interleukin-10, 0.4 μL / mL interleukin-13 and 0.5 μL / mL interleukin-18, and the rest is SCGM serum-free medium.
[0059] The late rehydration medium is: 0.3 μL / mL interleukin-10, 0.6 μL / mL interleukin-13 and 0.7 μL / mL interleukin-18, and the rest is SCGM serum-free medium.
[0060] The NK cell culture medium is: 2g / L L-lysine, 0.6g / L methionine, 2g / L L-tryptophan, 2g / L L-proline, 10g / L glutathione, 9g / L coenzyme 1, 2g / L silk peptide powder, 70mL / L human plasma, 12g / L human serum albumin, 0.18μL / mL interleukin-10, 0.4μL / mL interleukin-13, 0.5μL / mL interleukin-18, and the rest is SCGM serum-free culture medium.
[0061] Example 3
[0062] A method for improving the killing activity of NK cells, comprising the following steps:
[0063] (1) collecting peripheral blood, separating and collecting human peripheral blood mononuclear cells using a lymphocyte separation solution, and washing to obtain human peripheral blood mononuclear cells;
[0064] (2) Isolating NK cells from PBMC cells using an NK cell isolation kit;
[0065] (3) The obtained NK cells were inoculated in NK cell culture medium and cultured for 14 days; the culture temperature was 37°C, the volume concentration of CO2 was 5%; the inoculated cell density was 8×10 5 Pieces / mL.
[0066] (4) During the 0th to 7th day of culture, the early rehydration medium was added every 3 days, and the late rehydration medium was added every 3 days thereafter; the cell density was always maintained at 8×10 5 Pieces / mL.
[0067] The initial rehydration medium is: 65 mL / L human plasma, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13 and 0.4 μL / mL interleukin-18, and the rest is Lonza X-VIVO 15 serum-free medium.
[0068] The late rehydration medium is: 0.25 μL / mL interleukin-10, 0.55 μL / mL interleukin-13 and 0.65 μL / mL interleukin-18, and the rest is Lonza X-VIVO 15 serum-free medium.
[0069] The NK cell culture medium comprises: 1.5 g / L L-lysine, 0.4 g / L methionine, 1.5 g / L L-tryptophan, 1.5 g / L L-proline, 8 g / L glutathione, 7 g / L coenzyme 1, 1.5 g / L silk peptide powder, 65 mL / L human plasma, 10 g / L human serum albumin, 0.17 μL / mL interleukin-10, 0.3 μL / mL interleukin-13, 0.4 μL / mL interleukin-18, and the rest is Lonza X-VIVO 15 serum-free culture medium.
[0070] In Comparative Example 1, the other methods are the same as those in Example 3, except that interleukin-10, interleukin-13 and interleukin-18 in the NK cell culture medium are replaced by equal amounts of interleukin 15, interleukin 18 and interleukin 21.
[0071] In Comparative Example 2, the other methods are the same as those in Example 3, except that interleukin-10, interleukin-13 and interleukin-18 in the early rehydration medium and the late rehydration medium are replaced with equal amounts of interleukin 15, interleukin 18 and interleukin 21.
[0072] Comparative Example 3: Other methods are the same as those of Example 3, except that L-lysine, methionine, L-tryptophan and L-proline are not added to the NK cell culture medium.
[0073] Comparative Example 4: Other methods are the same as those in Example 3, except that glutathione and silk peptide powder are not added to the NK cell culture medium.
[0074] Experimental Example 1
[0075] The number of NK cells in the culture process of Example 3 and Comparative Examples 1 to Comparative Examples 4 was counted, and the expansion multiple was calculated. Two parallel tests were performed in each group, and the results were averaged, as shown in Table 1.
[0076] Table 1 Cell expansion times
[0077] Group No. 0d No. 3d No. 7d 11d 14d Example 3 1 27.6 68.5 124.3 211.6 Comparative Example 1 1 25.5 59.3 112.4 201.3 Comparative Example 2 1 25.1 57.6 108.5 195.7 Comparative Example 3 1 23.2 49.8 101.2 183.4 Comparative Example 4 1 24.3 58.7 96.4 178.2
[0078] From the contents recorded in Table 1, it can be seen that the culture method provided by the present invention can expand more than 200 times after culturing for 2 weeks, indicating that the method of the present invention can effectively promote the expansion of NK cells.
[0079] Experimental Example 2
[0080] Take the NK cells cultured in Example 3 and Comparative Examples 1 to Comparative Examples 4, and resuspend the cells in RPMI1640 medium to 1×10 6 The cells / mL cell suspension is ready for use;
[0081] K562 (human chronic myeloid leukemia cells) were used as target cells and the cells were resuspended in RPMI1640 medium containing 2% FBS to a concentration of 1×10 5 The cells / mL cell suspension is ready for use;
[0082] In each test group, cells were inoculated into a 96-well plate at effector-target ratios of 1:1, 5:1, and 10:1, and effector cell wells and target cell wells were set. Five replicate wells were inoculated for each culture method and cultured at 37°C, 5% CO2 for 24 h. The absorbance value was measured using the MTT method, and the killing rate was calculated. The results were averaged and are shown in Table 2 below.
[0083] Table 2 Killing rate
[0084] Group 1:1 5:1 10:1 Example 3 29.54% 75.38% 88.14% Comparative Example 1 24.33% 68.52% 82.62% Comparative Example 2 22.34% 65.26% 80.75% Comparative Example 3 27.52% 71.14% 84.34% Comparative Example 4 26.34% 70.29% 83.06%
[0085] From the contents recorded in Table 2, it can be seen that the NK cells cultured in the present invention have excellent killing effect, which can reach up to 88.14%, which is significantly better than other comparative examples.
[0086] From the data obtained from Comparative Examples 1 to 4, it can be seen that the selection of interleukin types is very important, and its effect on the killing effect of NK cells is the most significant, and the addition of amino acids, glutathione and silk peptide powder have the most significant effect on the expansion of NK cells. Therefore, in the process of NK cell culture, it is necessary to select the appropriate interleukin type, otherwise it will affect the killing effect of NK cells, and only when the complete component selection of the present invention is used can the best culture effect be achieved.
[0087] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for improving the killing activity of NK cells, characterized in that: The steps include: (1) Separating peripheral blood to obtain PBMC cells; (2) separating the PBMC cells to obtain NK cells; (3) inoculating NK cells into NK cell culture medium for cultivation; The NK cell culture medium comprises: 1-2 g / L L-lysine, 0.2-0.6 g / L methionine, 1-2 g / L L-tryptophan, 1-2 g / L L-proline, 6-10 g / L glutathione, 5-9 g / L coenzyme 1, 1-2 g / L silk peptide powder, 60-70 mL / L human plasma, 8-12 g / L human serum albumin, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13, 0.3-0.5 μL / mL interleukin-18, and the rest is a basic culture medium.
2. A method for improving the killing activity of NK cells according to claim 1, characterized in that: The basic culture medium is Lonza X-VIVO 15 serum-free culture medium, SCGM serum-free culture medium or Takara NK cell serum-free culture medium.
3. A method for improving the killing activity of NK cells according to claim 1, characterized in that: The culture temperature is 37-38° C., and the volume concentration of CO 2 is 5%-6%.
4. A method for improving the killing activity of NK cells according to claim 1, characterized in that: The culture time is 13 to 15 days.
5. A method for improving the killing activity of NK cells according to claim 1, characterized in that: The inoculated cell density is 7-9×10 5 Pieces / mL.
6. The method for improving the killing activity of NK cells according to claim 1, characterized in that: During the culture process, the early replenishment medium is added every 2 to 3 days from the 0th to the 7th day of culture, and the late replenishment medium is added every 2 to 3 days thereafter; after replenishment, the cell density is always maintained at 7 to 9×10 5 Pieces / mL.
7. A method for improving the killing activity of NK cells according to claim 6, characterized in that: The preliminary rehydration culture medium comprises: 60-70 mL / L human plasma, 0.16-0.18 μL / mL interleukin-10, 0.2-0.4 μL / mL interleukin-13 and 0.3-0.5 μL / mL interleukin-18, and the rest is basal culture medium.
8. A method for improving the killing activity of NK cells according to claim 6, characterized in that: The late-stage supplementation culture medium includes: 0.2-0.3 μL / mL interleukin-10, 0.5-0.6 μL / mL interleukin-13 and 0.6-0.7 μL / mL interleukin-18, and the rest is a basic culture medium.
9. Use of NK cells prepared by the method for improving the killing activity of NK cells according to any one of claims 1 to 8 in the preparation of anti-tumor drugs.
10. The use according to claim 9, characterized in that: The tumor is non-small cell lung cancer, chronic myeloid leukemia, colorectal cancer or breast cancer.
Citation Information
Patent Citations
Natural killer cell culture medium and natural killer cell amplification culture method
CN104593324A
Natural killer cell culture medium and multiplication culture method for natural killer cells
CN107488631A
Genetically modified cell strains for activating and amplifying NK cells and uses thereof
CN115461451A
Culture medium and culture method for promoting antitumor activity of NK (Natural Killer) cells
CN117721079A
Medium for ex vivo amplification of canine natural killer cells and ex vivo culturing method of canine natural killer cells using same
KR101499345B1
